Original Title: 과민성 장 증후군의 질병부담 추계

Authors' recommendations: During a single year of 2008, the prevalence of IBS was 5.1% in males and 6.9% in females, yielding a female/male ratio of 1.44. According to the survey, the estimation of patients' quality of life by using the EQ-5D tool resulted in a score of 0.889 that was lower than the score (EQ-5D index) of 0.933 that was obtained by the general population in Korea. The total expenditure in 2008 for healthcare services and pharmacy services related to IBS, as estimated from the claims data from the HIRA, was approximately 349.9 billion won. The other costs were estimated to be transportation costs (90.3 billion won), direct costs (440.2 billion won), and loss of productivity (145.2 billion won). Thus, the total burden of irritable bowel syndrome was estimated to be 585.4 billion won. The ratio of medical costs was the highest at 60.0%, followed by transportation costs at 15.4% and productivity loss costs at 24.8%. If other medical costs incurred by patients, such as over-the-counter drug costs and health food costs, are added to the aforementioned costs, the total amount is estimated to be 773.8 billion won.

Project Status: Completed

Year Published: 2011

URL for published report: https://www.neca.re.kr/lay1/program/S1T11C145/report/view.do?seq=7

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: South Korea

Organisation Name: National Evidence-based healthcare Collaborating Agency

Contact Address: National Evidence-based Healthcare Collaborating Agency (NECA), 3~5F Health and Welfare Social Administration B/D, 400 Neungdong-ro, Gwangjin-gu, Seoul, Korea.

Contact Name: int@neca.re.kr

Contact Email: int@neca.re.kr

Copyright: National Evidence-based Healthcare Collaborating Agency (NECA)